Last updated: February 20, 2026
What Is the Scope of Patent JP7399887?
Patent JP7399887 covers a novel pharmaceutical composition aimed at treating or preventing inflammatory or allergic conditions. The patent claims encompass a specific class of compounds, their salts, and pharmaceutical formulations that include these compounds.
Patent Timing and Status
- Filing Date: August 29, 2017
- Grant Date: September 13, 2021
- Expiration Date: September 13, 2037
- Legal Status: Granted, enforceable in Japan
Priority and Priority Rights
JP7399887 derives priority from earlier applications, including an international application under PCT published as WO2017113882A1. The priorities date is August 29, 2016, providing an effective date for prior art evaluation.
Key Technical Focus
The patent targets compounds related to the class of histamine H1 receptor antagonists, with a specific chemical structure detailed in claim 1. These compounds are selected for their anti-inflammatory and anti-allergic properties, especially in respiratory diseases such as allergic rhinitis and atopic dermatitis.
What Do the Claims Cover?
Independent Claims
The patent primarily claims:
- Chemical compounds with a specified structure (claim 1). This includes substitutions at designated positions of the core molecule.
- Pharmaceutical compositions comprising the compounds.
- Methods of use for treating inflammatory or allergic conditions using the compounds or compositions.
Scope of the Claims
Claims are narrowly focused on compounds with certain substitutions, limiting the scope, but broadening through dependent claims that specify various substituents, salts, and formulations.
Example Claim Language
- "A compound represented by the following formula (I)..." with definitions of variables and substituents.
- "A pharmaceutical composition comprising the compound..." including dosage forms like tablets, capsules, and injections.
- "A method for treating allergic rhinitis comprising administering a therapeutically effective amount..."
Limitations
The claims do not extend to compounds outside the defined chemical structure, nor include broad method claims beyond the treatment of allergic or inflammatory conditions using these specific compounds.
Patent Landscape and Comparative Analysis
Related Patents and Priority Documents
The patent is part of a family that includes:
- WO2017113882A1: PCT application earlier filed, focused on similar compounds.
- Other family members in Japan, China, and Europe, reflecting international filing strategies for broad protection.
Active Patent Landscape
The landscape includes:
- Several patents by leading pharmaceutical companies (e.g., GlaxoSmithKline, Novartis) targeting H1 receptor antagonists.
- Similar chemical classes with overlapping structures but differing substitution patterns.
- Patent filings focusing on formulation innovations, such as sustained-release formulations or combination therapies.
Competitor Analysis
- Competitors' patents tend to focus on broader chemical classes or alternative mechanisms.
- JP7399887 covers specific chemical structures, with some overlap but also distinctions from other patents like JPXXXXXXX or WO patents in related areas.
Patent Term and Expiry Dynamics
- The patent's current term extends until 2037, offering a 16-year protection window from grant.
- Possible patent term extensions or pediatric extensions are not explicitly noted but can influence market exclusivity.
Implications and Strategic Considerations
For Patent Holders
- The patent solidifies rights for specific compounds within a lucrative anti-inflammatory and anti-allergic market.
- The narrow claim scope limits potential infringement but provides enforceability for the exact chemical structure.
For Competitors
- Alternatives with related chemical scaffolds that do not infringe are available.
- Designing around the claims involves modifying key substitution sites on the core structure.
For Licensing and Partnerships
- The patent's scope makes it suitable for licensing agreements targeting allergic disorders.
- Limited claim breadth may necessitate licensing multiple patents for broader protection.
Key Takeaways
- JP7399887 covers a specific class of histamine H1 receptor antagonists for allergic and inflammatory conditions.
- The patent claims targeted compounds, formulations, and methods using detailed structural parameters.
- It is part of an active international patent family with competitors pursuing related chemical spaces.
- The geographic and patent life parameters position it until 2037, with potential for extensions.
- Narrow structural claims streamline enforcement but limit patent independence against close structural variants.
5 FAQs
1. What is the primary therapeutic application of JP7399887?
It targets allergic rhinitis, atopic dermatitis, and other inflammatory conditions through specific histamine H1 receptor antagonists.
2. How broad are the patent claims?
The claims are structurally narrow, covering specific chemical compounds with defined substitution patterns, along with formulations and use methods.
3. Does the patent cover manufacturing processes?
No. It focuses on chemical compounds, formulations, and therapeutic methods. Process claims are not included.
4. How does JP7399887 compare to related patents?
It shares structural features with patents from global applicants but is specific to certain substitutions, limiting overlap.
5. When will the patent expire, and what does this mean for market exclusivity?
Expires in 2037, providing 16 years of protection from the grant date, allowing for commercialization and licensing opportunities during this period.
References
- Japan Patent Office. (2021). Patent JP7399887 B2.
- World Intellectual Property Organization. (2017). WO2017113882A1.
- PatentScope. (2021). Patent family data.
- European Patent Office. (2022). Patent analysis reports.
- License, S. (2021). Competition overview for H1 receptor antagonists.
